Psoriasis: A systemic disease

被引:11
|
作者
Bens, Guido [1 ]
Maccari, Francois [2 ]
Esteve, Eric [1 ]
机构
[1] Hop Porte Madeleine, Ctr Hosp Reg Orleans, Serv Dermatol, F-45032 Orleans 1, France
[2] Hop Instruct Armees Begin, Serv Dermatol, F-94160 St Mande, France
来源
PRESSE MEDICALE | 2012年 / 41卷 / 04期
关键词
PLASMACYTOID DENDRITIC CELLS; CARDIOVASCULAR RISK-FACTORS; MYOCARDIAL-INFARCTION; PLAQUE PSORIASIS; COHORT; INFLAMMATION; MECHANISMS; LYMPHOMA; MODERATE; LINKS;
D O I
10.1016/j.lpm.2011.09.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Psoriasis is an inflammatory immune-mediated disorder which mainly affects the skin but which also has pathogenic effects with systemic impact. It represents a major psychological burden. During the post decade, inflammatory, cardiovascular, metabolic, and neuropsychiatric comorbidities of psoriasis have been described, especially in young patients with severe psoriasis. Whether psoriasis is an independent risk factor for these comorbidities remains a topic of scientific debate. Interpretation of available epidemiologic data is complex because of bias concerning data recruitment in the studies and non-consideration of other confounding risk factors and employed treatment. The hypothesis of on etiologic role of psoriasis in its cardiovascular and metabolic comorbidities is powered by p concepts establishing a link between chronic inflammation in psoriasis, endothelial dysfunction, formation of atherosclerotic plaques, and the different compounds of metabolic syndrome. Since psoriasis is recognized as a systemic disease, patient management has to be multidisciplinary. It implicates identification and treatment of psychological disorders, addictions, and associated cardiovascular and metabolic diseases. Preliminary experimental and epidemiological data indicate that adequate systemic treatment of psoriasis may prevent some comorbidities.
引用
收藏
页码:338 / 348
页数:11
相关论文
共 50 条
  • [31] Breastfeeding and systemic agents for psoriasis
    Little, Sarah
    Fenner, Sarah
    BRITISH JOURNAL OF GENERAL PRACTICE, 2019, 69 (681): : 177 - 177
  • [32] Atherosclerosis as a systemic feature of psoriasis
    Alexandroff, A. B.
    Pauriah, M.
    Lang, C. C.
    Struthers, A. D.
    Armstrong, D. J.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2011, 36 (05) : 451 - 452
  • [33] Systemic Drug Therapy in Psoriasis
    Moessner, R.
    Schoen, M. P.
    AKTUELLE DERMATOLOGIE, 2010, 36 (04) : 142 - 152
  • [34] NEW SYSTEMIC THERAPIES FOR PSORIASIS
    WEBER, G
    FREY, H
    NEUGEBAUER, D
    HAUTARZT, 1985, 36 (01): : 20 - 24
  • [35] SYSTEMIC RETINOID THERAPY FOR PSORIASIS
    LOWE, NJ
    LAZARUS, V
    MATT, L
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1988, 19 (01) : 186 - 190
  • [36] New Systemic Therapies for Psoriasis
    Mansouri, Yasaman
    Goldenberg, Gary
    CUTIS, 2015, 95 (03): : 155 - 160
  • [37] Choosing Systemic Agents for Psoriasis
    Kontzias, Christina
    Chandy, Rithi
    Feldman, Steven R.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (03) : 333 - 337
  • [38] SYSTEMIC TREATMENT OF PSORIASIS - REVIEW
    ZACHARIAE, H
    HAUTARZT, 1976, 27 (12): : 569 - 573
  • [39] Advances in systemic therapy for psoriasis
    Mrowietz, U
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (04) : 362 - 367
  • [40] Psoriasis and Systemic Inflammatory Disorders
    Tashiro, Tomoko
    Sawada, Yu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (08)